Search
Search Results
##search.searchResults.foundPlural##
-
CMV MANAGEMENT WITH SPECIFIC IMMUNOGLOBULINS: A MULTICENTRIC RETROSPECTIVE ANALYSIS ON 92 ALLOTRANSPLANTED PATIENTS. Anti-CMV immunoglobulins for CMV treatment
1930PDF: 1161HTML: 265 -
EARLY PREDICTIVE VALUE OF PERIPHERAL INFLAMMATORY INDEX COMBINED WITH HIGH-SENSITIVITY TROPONIN T FOR SEPSIS-INDUCED CARDIOMYOPATHY Inflammatory and Troponon T in cardiomyopaty from Sepsis
172PDF: 182HTML: 13 -
OUTCOME OF ANTIFUNGAL COMBINATION THERAPY FOR INVASIVE MOLD INFECTIONS IN HEMATOLOGICAL PATIENTS IS INDEPENDENT OF THE CHOSEN COMBINATION
1094PDF: 541HTML: 1689Figures: 166Fifures Sanz: 176tables Sanz: 180Untitled: 176 -
Coronavirus disease 2019 (COVID-19) severity in patients with thalassemias: A Nationwide Iranian Experience Coronavirus in patients with thalassemias
1340PDF: 464HTML: 166 -
-
-
NURSES’ PHYSICAL AND PSYCHOLOGICAL SYMPTOMS DURING THE FIRST COVID-19 LOCKDOWN IN ITALY A nationwide cross-sectional study in stem cell transplantation setting.
1776PDF: 816HTML: 226 -
Pseudo-differentiation syndrome
1342PDF: 657HTML: 10846Figure 1: peripheral blood showing myeloblasts with auer rods: 117Figure 2: CXR upon presentation to the hospital- no infiltrates nor consolidation changes: 103Figure 3: CXR showing pulmonary infiltartes with consolidation: 136Figure 4: CXR after starting steroid therapy- where the infiltrates have melted away: 109Figure 5: barograph showing the rising TLC ad ANC values- associated with worsening symptoms and increasing pulmonary infiltrates in CXR: 118 -
WHAT ARE FUNGAL INFECTIONS?
4164PDF: 2369HTML: 27593de Pauw: 235 -
EVALUATION OF USING EMPIRIC GLYCOPEPTIDES IN ACCORDANCE WITH THE IDSA GUIDELINE IN HEMATOLOGIC MALIGNANCY PATIENTS WITH FEBRILE NEUTROPENIA Empiric glycopeptide use in neutropenic fever
1451PDF: 1052HTML: 215 -
Ceftolozane-Tazobatam for febrile neutropenia treatment in hematologic malignancy patients colonized by multi-resistant Enterobacteriaceae: preliminary results from a prospective cohort study Ceftolozane-Tazobatam for febrile neutropenia
7832PDF: 717HTML: 211 -
-
CYTOMEGALOVIRUS REACTIVATION IN ADULT RECIPIENTS OF AUTOLOGOUS STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE
1544PDF: 877HTML: 978figures: 177table 1: 180table2: 179table3: 180 -
AUTOIMMUNE CYTOPENIAS IN CHRONIC LYMPHOCYTIC LEUKEMIA, FACTS AND MYTHS
2173PDF: 1197HTML: 3709 -
Common variable immunodeficiency due to a novel NFKB1 variant in a child with thalassemia major CVID with thalassemia major
688PDF: 549HTML: 162 -
HEMATOPOIETIC STEM CELL TRANSPLANTATION IN SEVERE PEDIATRIC SICKLE CELL DISEASE: OUTCOME AND LONG-TERM COMPLICATIONS, SAUDI EXPERIENCE AT KING FAISAL SPECIALIST HOSPITAL, RIYADH, SAUDI ARABIA HCT in in Severe Pediatric Sickle Cell Disease
1171PDF: 925HTML: 348 -
How I treat acute and persistent sickle cell pain
1912PDF: 1114HTML: 485 -
LYON-UNIVERSITY HOSPITAL EXPERIENCE WITH GEMTUZUMAB OZOGAMICIN THERAPY IN ACUTE MYELOID LEUKEMIA: A ‘REAL-LIFE’ STUDY Gemtuzumab ozogamicin in AML
1713PDF: 1161HTML: 245 -
FIRST TUNISIAN CLUSTER ADMISSIONS OF CRITICALLY ILL PATIENTS WITH MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN (MIS-C) : Multisystem inflammatory syndrome in children (MIS-C)
1311PDF: 502HTML: 190 -
Flow Cytometry Method as a Diagnostic Tool for Pleural Fluid Involvement in a Patient with Multiple Myeloma
1410PDF: 724HTML: 4550Figure 1: Chest radiograph: 209Figure 2: Flow cytometer analysis of pleural fluid: 183 -
HOMOZYGOUS DELETION ALFA-THALASSEMIA AND HEREDITARY PERSISTENCE OF FETAL HEMOGLOBIN, TWO GENETIC FACTORS PREDICTIVE THE REDUCTION OF MORBIDITY AND MORTALITY DURING PREGNANCY IN SICKLE CELL PATIENTS . A REPORT FROM DEMOCRATIC REPUBLIC OF CONGO ALPHA THALASSEMIA AND HEREDITARY PERSISTENCE OF FETAL HEMOGLOBIN REDUCE MORBIDITY DURING PREGNANCY IN SICKLE CELL PATIENTS
9968PDF: 983HTML: 210 -
COMPARISON OF INFECTIOUS COMPLICATIONS IN PATIENTS RECEIVING HIGH-DOSE CYCLOPHOSPHAMIDE AS GVHD AFTER TRANSPLANTATION FROM A 9/10 HLA-MATCHED UNRELATED DONOR WITH STANDARD GVHD PROPHYLAXIS AFTER TRANSPLANT FROM A FULL MATCHING DONOR Infection With PTCy Versus Standard GvHD Prophylaxis
1374PDF: 1303HTML: 96







